Navigation Links
Superior Efficacy-dose Ratio for Lantus(R) Over detemir
Date:9/30/2009

PARIS, September 30 /PRNewswire-FirstCall/ --

- 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R)

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

To view the Multimedia News Release, please click:

http://www2.prnewswire.com/mnr/sanofiaventis/40283/

In the head-to-head, randomised, non-inferiority controlled clinical trial of 964 patients, patients taking Lantus(R) required an average daily dose of 43.5 units to achieve the primary endpoint of HbA1c below 7% without symptomatic hypoglycaemia compared to patients on insulin detemir, who received 76.5 units - an increase of 76% (p<0.001). Despite lower doses of insulin in the glargine group, Lantus(R) once-daily and insulin detemir twice-daily resulted in similar improvements in glycemic control (HbA1c) and a similar risk of hypoglycaemia (primary endpoint: 27.5% vs 25.6%, p=0.52). Patients in the Lantus(R) arm of the study also achieved significantly lower fasting blood glucose (-63.1 mg/dL Lantus(R) vs -57.7 mg/dL, p<0.001).

"This study demonstrated that for insulin-naive patients with type 2 diabetes, initiating insulin therapy with once-daily glargine achieved the same glycemic control as twice-daily detemir, with somewhat more weight gain, but lower insulin doses", stated Study Investigator Hertzel Gerstein, Professor of Diabetes Medicine
'/>"/>

SOURCE Sanofi Aventis Groupe
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Reaffirms Superiority of Trofile(TM) Assay
2. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
3. Flurizans Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimers Disease is Superior to That of Aricept
4. By adding graphene, researchers create superior polymer
5. Increasing Sales Productivity Through Superior Sales Force Performance Management
6. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
7. InVitrias Cellastim Delivers Superior Results in Mammalian Cell Culture
8. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
9. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
10. UB engineers prove that carbon nanotubes are superior to metals for electronics
11. AACR 100th Annual Meeting Highlights Superior Ability of InNexus DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 According to a new market ... - Global Industry Analysis, Size, Share, Growth, Trends and ... is estimated at USD 161,056.5 million in 2014 and ... from 2014 to 2020, to reach an estimated value ... drugs market is witnessing a significant growth due to ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... 2011 Operational and Financial Results ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Nov. 11, 2010 StemCyte, Inc., one of the ... companies, is proud to announce that the Company has ... U.S. Internal Revenue Service,s Qualifying Therapeutic Discovery Project (QTDP) ... fewer than 250 employees. The Patient Protection ...
... (Nasdaq: ARAY ), a global leader in the ... to present at the Lazard Capital Markets, Healthcare Conference in ... a.m. ET/7:30 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
Cached Biology Technology:YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 9YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 10YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 11YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 12YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 13YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 14StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP) 2Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets' Healthcare Conference 2
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... experts gathered at NJIT this week for an all-day ... U.S. Environmental Protection Agency (EPA) to dredge toxic sediment ... , The EPA has called the plan, which proposes ... capping sections of the riverbed, one of the largest ... be dredged and disposed off-site. , "We need to ...
(Date:7/24/2014)... To reduce fire hazard in the United States, wildland ... woody shrubs and suppressed trees (ladder fuels). These ... periods of low fire danger in order to dispose ... hazardous air pollutants, managers often cover all or part ... referred to as agricultural plastic, in order to keep ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... to the growing list of genetic variants that determine ... by Cell Press on December 30 in the ... previously unknown variants associated with height and might provide ... Although environmental variables can impact attained adult height, ...
... large quantities of nitrate-rich fertilizer to realize optimal ... to balance the amount of nitrogen needed for ... leach into ground and surface waters. Increased interest ... to identify genotypes that have a characteristic called ...
... producers have traditionally relied heavily on hand thinning, a ... increasing labor costs and a limited workforce, peach and ... such as string thinners to minimize the need for ... promising results when it was evaluated in four U.S. ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... of X-ray crystallography services for structure-based ... to its pharmaceutical and biotechnology clients. ... drug-like fragments to the active sites ... scientists to develop novel, high-affinity inhibitors. ...
...
... monitoring acetylcholinesterase (AChE) activity. This is a ... min), non-radioactive and easy to use assay ... substrate, acetylcholine. A series of coupled enzyme ... into a change in luminescence. Inhibitors of ...
Biology Products: